- 1 Antenatal corticosteroids for pregnant women at risk of preterm labor in low- and middle-
- income countries: utilization and facility readiness 2
- 4 **Authors information**

9

- Wen-Chien Yang (0000-0001-8206-1496)<sup>1\*</sup>; Catherine Arsenault (0000-0003-2410-3015)<sup>1</sup>; 5
- Victoria Y. Fan (0000-0001-7755-9425)<sup>2,3</sup>; Hannah H. Leslie (0000-0002-7464-3645)<sup>4</sup>; Fouzia 6
- Faroog (0000-0001-6491-6323)<sup>1</sup>; Andrea B. Pembe (0000-0002-8090-3298)<sup>5</sup>; Theodros 7
- Getachew (0000-0002-6486-0531)<sup>6</sup>: Emily R. Smith (0000-0001-5715-9459)<sup>1,7</sup> 8
- 1. Department of Global Health, Milken Institute School of Public Health, The George 10
- Washington University, Washington, DC, USA 11
- 2. Center for Global Development, Washington, DC, USA 12
- 3. College of Social Sciences, University of Hawai'i at Mānoa, Honolulu, HI, USA 13
- 14 4. Division of Prevention Science, University of California San Francisco, San Francisco, CA,
- 15 **USA**

21

- 5. School of Clinical Medicine, Muhimbili University of Health and Allied Sciences, Dar es 16
- Salaam, Tanzania 17
- 6. Ethiopian Public Health Institute, Addis Ababa, Ethiopia 18
- 7. Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The 19
- 20 George Washington University, Washington, DC, USA
- \*Corresponding author: Wen-Chien Yang, MD, MPH 22
- 23 Address: 950 New Hampshire Ave, NW, Washington DC, 20037

Telephone: 617-794-2209 Email: wenchienyang@gwmail.gwu.edu **Source(s) of support:** This study was not funded. Word count: 3075 Number of figures and tables: 4 

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

**ABSTRACT Background** Antenatal corticosteroids (ACS) use among pregnant women with a high likelihood of preterm labor improves newborn survival. ACS adoption in low- and middle-income countries (LMICs) remains limited. Giving ACS in inadequately equipped settings could be harmful to mothers and newborns. Thus, health facilities have to demontrate readiness to administer ACS. However, the degree to which health systems are ready is unknown. **Objective** We assessed facility readiness to administer ACS based on the 2022 WHO recommendations on ACS use and ACS utilization. Methods The study used Service Provision Assessment surveys administered between 2013 and 2022 in nine LMICs. The primary outcome was whether facilities had ever provided ACS. We also assessed injectable corticosteroid (dexamethasone or betamethasone) availability and facility readiness to administer ACS. We used a total of 35 indicators, grouped into four readiness categories based on the WHO recommendations, to measure facility readiness. **Findings** Across eight countries with comparable sampling strategies, only 10.7% (median, range 6.7% -35.2%) of facilities had ever provided ACS; one-fourth (median 25.3%, range 4.6% - 61.5%) of facilities had injectable corticosteroids available at the time of the survey; overall readiness indices were low ranging from 8.1% for Bangladesh to 32.9% for Senegal. Across four readiness categories, the readiness index was the lowest for criterion 1 (ability to assess gestational age

accurately and identify a high likelihood of preterm birth) (7.3%), followed by criterion 2 (ability to identify maternal infections) (24.8%), criterion 4 (ability to provide adequate preterm care) (31.3%), and criterion 3 (ability to provide adequate childbirth care) (32.9%). Conclusion We proposed a strategy for measuring facility readiness to implement one of the most effective interventions to improve neonatal survival. Countries should operationalize readiness measurement, improve facilities readiness to deliver this life-saving intervention, and encourage ACS uptake by targeting facilities that are well-equipped.

#### INTRODUCTION

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Antenatal corticosteroids (ACS) use among pregnant women at risk of preterm labor is one of the most effective interventions to improve neonatal outcomes. By accelerating fetal lung maturity, ACS can reduce the risk of respiratory distress syndrome by 30% and neonatal death by 20%.(1) The World Health Organization (WHO) and other professional medical organizations recommend giving ACS to pregnant women at risk of imminent preterm labor from gestational age (GA) of 24 to 34 weeks.(2-5) While ACS is commonly used in high-income countries, its adoption remains extremely limited in low- and middle-income countries (LMICs) despite LMICs contributing to 80% of preterm births worldwide.(6) An estimated 13.4 million newborns were born prematurly in 2020.(7) Globally, preterm births are the leading cause of neonatal death, accounting for nearly half (46%) of under-five moratlity (U5M).(8) Additionally, 75% of all neonatal deaths occur in the first week of life, with 1 million neonatal deaths happening within the first 24 hours after birth (9, 10), which motivates the interventions targeting this critical period.(11, 12) ACS has been considered "the lowest-hanging and sweetest fruit" as an intervention to improve preterm outcomes in LMICs.(13) However, ACS uptake in LMICs has been a subject of widespread debate.(13-18) Two major evidence gaps remain. First, the current status of ACS use in LMICs is unknown despite some outdated coverage data. Second, the structural readiness of health facilities in LMICs to provide ACS based on international guidelines is unclear. In 2022, the WHO released its recommendations emphasizing five conditions for safe and effective administration of ACS: 1) GA can be accurately assessed, 2) there is a high likelihood of preterm birth within 7 days of starting ACS therapy, 3) there is no evidence of maternal infections, 4) adequate childbirth care is available, and 5) the preterm newborn can receive adequate care.(2)

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

The WHO recommendations caution that these five conditions might not be met consistently across settings because of varied capabilities, highlighting the potential harms of ACS in places lacking the capacity to meet the criteria.(2). As a potent anti-inflammatory drug, ACS suppresses immune functions. Maternal infections remain a major concern if ACS is given to vulnerable pregnant women who are ineligible for this intervention. Also, observational studies found increased neurocognitive disorders among late preterm infants (born at GA 34 to 36 weeks) who were exposed to ACS.(19-21) The balance between the benefits and risks emphasized the importance of locations in which ACS should be given. However, knowledge about facility readiness in resource-constraint settings remains scarce. In 2021, Kankaria et al. found that primary and secondary facilities in northern India were not ready to administer ACS safely, which is, to date and to our knowledge, the only study assessing facility readiness to give ACS.(22) As facility readiness is crucial in providing healthcare of good quality (23), there is an urgent need to expand evidence on ACS use in low resource countries. This study aimed to address these knowledge gaps. The objectives were to assess ACS use, corticosteroid availability, and facility readiness to administer ACS according to the WHO criteria. **METHODS** Study sample This study used data from the Service Provision Assessment (SPA), a health facility survey on service availability and quality of care.(24) We restricted our analysis to SPAs done in the past 10 years and used the latest survey available for countries with SPA data. This study included 10 surveys from 9 countries: Afghanistan 2018-2019, Bangladesh 2017-2018, Nepal 2021, Haiti 2017-2018, the Democratic Republic of Congo (DRC) 2017-2018, Ethiopia 2021-2022, Malawi

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

2013-2014, Senegal 2018 and 2019, and Tanzania 2014-2015. All surveys were completed before the release of the 2022 WHO recommendations but most, except Malawi 2013-2014 and Tanzania 2014-2015 surveys, were conducted after the WHO recommendations on interventions to improve preterm birth outcomes in 2015, which contained guidelines on ACS use. (25) The sampling strategies varied based on country needs.(26-35) The majority of surveys adopted stratified random sampling strategies to obtain a national representative sample in the country.(26-28, 31, 32) Malawi 2013-2014 and Haiti 2017-2018 SPAs were national census.(33, 35) Unlike other surveys, Afghanistan 2018-2019 mainly sampled urban hospitals.(34) Senegal implemented continuous SPA over a consecutive 5 years to survey all health facilities. (29, 30, 36) In order to have similar sample sizes across countries, we merged two years (2018 and 2019) of data from Senegal (Supplemental Table 1). Our study used data from two core instruments (out of five) of the SPA survey questionnaire: facility inventory and health worker interviews. In each country, only facilities that provided antenatal care (ANC), performed normal deliveries, and/or performed Cesarean deliveries were included. Measures Our primary outcome was ACS utilization, defined as facilities that had ever provided ACS to pregnant women. We focused on two secondary outcomes: corticosteroid availability (injectable dexamethasone or betamethasone) and facility structural readiness. Most countries did not survey corticosteroid availability (except for Afghanistan 2018-2019) within the maternal and child health care sections in SPA surveys. We reported the availability of injectable corticosteroids that were surveyed in the section on medicines for non-communicable diseases. We assessed facility readiness to provide ACS in accordance with the 2022 WHO recommendations on ACS use. We identified 35 indicators from the SPA questionnaire, which

were grouped into four readiness categories based on the five WHO criteria (collapsing criterion 1 and criterion 2) as outlined in **Supplemental Table 2**. The first category focused on the facility's ability to assess GA accurately and to identify pregnant women with a high likelihood of preterm labor; we included only one indicator for this category (presence of a functional ultrasound). The second category included 4 indicators and covered the facility's ability to identify maternal infections. The third and fourth categories included 13 and 17 indicators and assessed the facility's readiness to provide adequate childbirth care and preterm newborn care, respectively. For each category, readiness indices were calculated by dividing the number of indicators available by the total number of indicators assessed, where higher percentages indicating higher readiness. An overall readiness index was calculated by averaging the readiness indices from four categories. This approach was chosen based on previous studies on facility readiness to implement health improvement interventions. (37, 38)

#### Statistical analysis

First, we presented descriptive statistics of ACS utilization, corticosteroid availability, and facility readiness indices, taking into account survey sampling weights. Results were stratified by three facility levels. Level 1 facilities were those that only provided ANC and did not conduct deliveries; ANC was defined as the care that pregnant women receive before birth, including risk identification, prevention, and management of pregnancy related health conditions, education, and health promotion.(39) Level 2 facilities performed normal deliveries, but not Cesarean deliveries, and level 3 facilities performed Cesarean deliveries. Because Afghanistan mainly sampled hospitals, which substantially differed from other countries, it was excluded from the summary descriptive analysis of our outcomes of interest and included only in analyses by facility levels.

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

Second, we assessed the relationships between ACS use and, respectively, ACS availability, and overall readiness indices at sub-national levels (e.g. regions in Ethiopia, provinces in DRC). This was driven by the hypothesis that facilities without corticosteroids or with low readiness might refer patients in need of ACS to facilities in geographic proximity. We averaged each of the three measures (ACS use, corticosteroid availability, and readiness index) for all facilities in each subnational region. Lastly, we examined the difference in the overall readiness index between facilities that had ever and never used ACS by country. All analyses were performed using R. **RESULTS** This study included a total of 8669 facilities from ten surveys in nine countries. All surveys had a high response rate (median 94.9%) ranging from 88.8% in Afghanistan to 99.0% in Tanzania (Supplemental Table 3). The majority (88.9%, median; range 66.1% - 98.8%) of facilities provided maternal health care services and were included in our analysis (Supplemental Table 3). The median sample size was 929 facilities (median; range 108 -1500) (**Table 1**). Among eight countries (excluding Afghanistan), 22.6% (median; range 7.1% - 88.7%) of facilities were urban. The proportion of facilities of different levels varied across countries. Across eight countries, one third (median 32%) of the facilities were level 1 facilities that provided antenatal care, with Bangladesh having the highest proportion (76.2%) of level 1 facilities and the DRC having the lowest proportion (1.9%). The proportion of level 2 facilities was 59.4% (median) with Tanzania having the highest proportion (83.3%) and Bangladesh with the lowest proportion (19.5%). Only 6.2% (median) of facilities were level 3 facilities that performed Cesarean deliveries, with 26.5% of facilities in DRC and 2.7% in Ethiopia were level 3 (**Table 1**).

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

ACS utilization. ACS was underutilized across all countries. Excluding Afghanistan, median ACS use was 10.7%, ranging from 6.7% of facilities in Bangladesh to 35.2% of facilities in the DRC having ever administered ACS (Figure 1a). In Afghanistan, 68.7% of facilities had administered ACS at the time of the survey. We did not find higher ACS use in surveys that were done in more recently. While none of the level 1 facilities had provided ACS, ACS use increased by facility level (**Figure 1b**). Within facility level across 9 countries, 21.6% (median, range 5.0% - 26.9%) of level 2 facilities and 76.3% (median, range 52.7% - 90.3%) of level 3 facilities had provided ACS. ACS availability. Corticosteroid availability was limited. Across eight countries, a fourth of the facilities (median 25.3%, range 4.6% - 61.5%) had at least one valid corticosteroid (injectable betamethasone or dexamethasone) available at the time of the survey, while 93.3% of facilities in Afghanistan had corticosteroids available (**Figure 1c**). Corticosteroid availability generally increased by facility level within each country (Figure 1d). Also, gaps between corticosteroid availability and ACS utilization existed. For example, 48.5% of level 2 facilities in Nepal had corticosteroid available at the time of survey but only 7.3% had ever used it (Supplemental Figure 5). Facility readiness. Readiness indices were low (Figure 2). Overall, only 22% of the facilities in the sample had an overall readiness index above 50%. Other than Afghanistan, overall readiness indices were low among the eight countries ranging from 8.1% in Bangladesh to 32.9% in Senegal. Afghanistan had an overall readiness index of 57.7%. We did not see higher overall readiness indices in surveys done in more recent years. Also, overall readiness indices increased by facility level. Across four readiness categories among 8 countries, facilities performed the worst in the ability to assess GA accurately, with a readiness index of 7.3% (median), followed

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

by the ability to identify maternal infection (median, 24.8%), provide adequate preterm care (median 31.3%), and provide adequate childbirth care (median 32.9%). When delving into the details of specific indicators among the 35 ones used, we found very limited availability for respiratory support-related equipment across countries in the readiness category of adequate preterm newborn care (Supplemental Table 4, Supplemental Figures 1-4). ACS use, availability, and readiness at sub-national levels. At the sub-national level, positive associations were observed between corticosteroid availability and ACS use as well as between average readiness and ACS use (Figures 3a and 3b). A few Ethiopian regions (Dire Dawa and Harari) had an average overall readiness index above 50% but low ACS use (<25%). In contrast, some regions of the DRC (Kasaï Central, Kongo Central, Kinshasa, and Haut-Katanga) had low overall readiness indices (<50%), but ACS use greater than 50% (**Figure 3b**). At the facility level, overall readiness indices differed between facilities that had ever and never provided ACS within each country (Supplemental Figures 6-8). In Afghanistan, Bangladesh, DRC, Senegal, and Tanzania, facilities that had utilized ACS had higher overall readiness indices compared to facilities that had never used ACS. On the contrary, the results were reversed for Nepal, Haiti, Ethiopia, and Malawi. **DISCUSSION** This study assessed antenatal corticosteroid use, corticosteroid availability and structural readiness to administer the drug adequately based on international recommendations among 8,669 health facilities from nine resource-constrained countries. We had three major findings: 1) antenatal corticosteroids were substantially underused, 2) corticosteroid availability was limited, and 3) facilities in these countries had low levels of readiness.

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

We found limited ACS use with only one out of ten health facilities having ever administered ACS. However, it is challenging to compare our results with existing literature as previous work mostly measured ACS coverage among pregnant women who delivered preterm infants.(40-45) A 2011 WHO maternal and newborn health survey for 29 countries found 54% of women who gave birth at GA 26 to 34 weeks were given ACS, with the lowest use in Afghanistan (16%), Nepal (20%), and DRC (16%).(41) Another analysis using the data from the 2015 Antenatal Corticosteroids Trial (ACT trial) showed an overall low ACS use in control clusters; in Kenya, only 3.8 % of pregnant women of infants born with birthweight less than the 5<sup>th</sup> percentile, a proxy for preterm births, received ACS.(40) Our findings adds value in understanding the status of ACS use at the facility level. Also, we found that only one third of the facilities in the sample had either injectable dexamethasone or betamethasone. Dexamethasone is on the WHO List of Essential Medicines, but limited availability remains a major barrier to ACS use. (46) Strategies to improve ACS coverage need to ensure drug availability. The location where ACS is given is crucial to ensure safe and effective use. Two landmark studies on the effects of ACS in LMICs presented conflicting results, highlighting the importance of settings in which ACS is given.(47, 48) The 2015 ACT trial, a cluster randomized trial of a multifaceted intervention to promote ACS use in six LMICs unexpectedly found increased neonatal deaths and suspected maternal infections among intervention clusters.(47) On the contrary, the WHO Antenatal Corticosteroids for Improving Outcomes in Preterm Newborns Trial (ACTION-I trial) in 2020, an RCT in five LMICs, showed ACS reduced neonatal deaths without increasing maternal infections.(48) These contradictory findings can partially be explained by the different settings for the two trials; the ACT trial was done in all levels of care including clinics and primary care centers, whereas the ACTION-I trials included secondary or

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

tertiary hospitals. (48) The drastically different findings emphasized the importance of locations – or more precisely, the readiness of facilities – in providing ACS. Our study offered a strategy for measuring facility readiness to implement this life-saving intervention. However, recommendations on what levels of facilities should give ACS need to be made carefully. Assuming essential equipment, medicines and trained staff are available, some level 2 and level 3 facilities with high readiness that have never provided ACS should be targeted for the expansion of ACS use. Also, our sub-national level analyses showed that some provinces in DRC with low overall readiness (<50%) frequently administered ACS. Policymakers should ensure that ACS is delivered in well-equipped settings. Another critical issue centers around the different aspects of readiness to ensure safe and effective ACS use. Our readiness index was developed based on the WHO criteria. However, it is debatable, first, whether some criteria could be met across facility levels, and second, whether facilities need to meet all criteria to safely and effectively administer ACS. For example, ultrasound examination in early pregnancy is the gold standard for GA assessment. However, we found that only 7.3% (median across eight countries, range 0.2% to 12.3%; 82.4% for Afghanistan) of maternal care facilities had a functional ultrasound. Access to ultrasound for GA dating remains a major barrier to proper ACS use despite its increasing use in obstetric care in LMICs.(17, 49) In this case, GA dating should occur early in pregnancy, while ACS use occurs later in pregnancy. Thus, the decision to administer ACS should not be based on the ultrasound availability in place, but the availability of accurate GA assessment (which may come from care obtained at another facility). In addition, regarding the WHO recommendations for adequate preterm newborn care, one important element is non-invasive respiratory support, such as continuous positive airway pressure (CPAP). However, this recommendation might exclude most

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

preterm infants who might benefit from ACS use because they usually do not have access to respiratory support in LMICs.(50) A similar concern applies to adequate childbirth care, referring to nine signal functions of Comprehensive Emergency Obstetric and Newborn Care (CEmONC), including blood transfusions and Cesarean sections. Again, it is debatable whether a facility can give ACS only when it can do blood transfusions. Our study had several strengths. To our knowledge, this is the first study to assess ACS use, availability and structural readiness to give ACS at the facility level. Also, we included data from multiple countries to understand the landscape of ACS use and identify policy directions in areas with a high burden of preterm births. Nonetheless, our study has a few limitations. First, sampling strategies and survey years varied across countries spanning 9 years. All surveys were done prior to the release of the 2022 WHO recommendations while most of them were completed after the release of 2015 WHO recommendations on interventions to improve preterm birth outcomes that contained guidelines on ACS utilization. (2, 25) Also, countries have different national guidelines regarding ACS use. One policy analysis on ACS use in Africa found ACS could be given in lower levels of care before referral in Ethiopia and Tanzania, but DRC and Malawi only allowed ACS use in hospitals.(51) Hence, we caution careful interpretations when comparing across countries. Secondly, some readiness indicators served as proxies. For instance, SPA surveys do not assess the availability of corticosteroids and ultrasound in the maternal care section. Instead, corticosteroid availability is surveyed in the section for medicines for non-communicable diseases, and ultrasound availability is assessed within the facility in general. We also used the availability of rapid diagnostic tests for HIV and syphilis as a proxy to estimate facilities' ability to detect maternal infections. This approach might overestimate or underestimate true availability or readiness. Thirdly, we were unable to

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

draw correlations between ACS use or facility readiness with preterm health outcomes because SPAs do not have patient-level data for newborns. Antenatal corticosteroid use has gained tremendous international attention as its population-level health benefits could be profound.(12, 52-55) ACS should not be used as a "just-in-case" intervention. (56) It should be given to the right people (pregnant women at risk of imminent preterm labor and without maternal infections), at the right time (the specified GA window), and in the right place (settings that are properly equipped and ready to provide quality maternal and newborn care). Future research and programs should operationalize readiness measurement and assess facility readiness for safe and effective ACS use to enhance readiness and encourage ACS uptake among well-prepared facilities. Disclosure of relationships and activities: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf and declare no support from any organization for submitted work; no financial relationships with any organization that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. **Supporting information** S1 Supplementary file

#### References

- 1. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020;12(12):Cd004454. Epub 2020/12/29. doi: 10.1002/14651858.CD004454.pub4. PubMed PMID: 33368142; PubMed Central PMCID: PMCPMC8094626 Stuart Dalziel reports receiving research funding, not associated with the review topic, from Cure Kids, Health Research Council, and Starship Foundation, New Zealand. Stuart Dalziel is employed by The University of Auckland and Auckland District Health Board. He is also on the board of the Advanced Paediatric Life Support New Zealand.
- 2. The World Health Organization. 2022 WHO recommendations on ACS to improve preterm birth outcomes. 2022. Epub 2022/09/29.
- 3. Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS. Society for Maternal-Fetal Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016. American journal of obstetrics and gynecology. 2021;225(5):B36-b42. Epub 2021/08/08. doi: 10.1016/j.ajog.2021.07.023. PubMed PMID: 34363784.
- 4. Norman J, Shennan A, Jacobsson B, Stock SJ, Birth FWGfP. FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm. Int J Gynaecol Obstet. 2021;155(1):26-30. Epub 2021/09/15. doi: 10.1002/ijgo.13836. PubMed PMID: 34520057.
- 5. El-Sayed YY, Borders AEB, Gyamfi-Bannerma C. ACOG committee opinion, Antenatal Corticosteroid Therapy for Fetal Maturation The American College of Obstetricians and Gynecologists. 2017;130(2):e102-e9.
- 6. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. The Lancet Global health. 2019;7(1):e37-e46. Epub 2018/11/06. doi: 10.1016/s2214-109x(18)30451-0. PubMed PMID: 30389451; PubMed Central PMCID: PMCPMC6293055.
- 7. Ohuma EO, Moller AB, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. Lancet (London, England). 2023;402(10409):1261-71. Epub 2023/10/08. doi: 10.1016/s0140-6736(23)00878-4. PubMed PMID: 37805217.
- 8. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals. The Lancet Child & adolescent health. 2022;6(2):106-15. Epub 2021/11/21. doi: 10.1016/s2352-4642(21)00311-4. PubMed PMID: 34800370; PubMed Central PMCID: PMCPMC8786667.
- 9. The World Health Organization. Newborn mortality 2024 [cited 2024 May 13]. Available from: https://www.who.int/westernpacific/news-room/fact-sheets/detail/newborn-mortality.
- 10. Sankar MJ, Natarajan CK, Das RR, Agarwal R, Chandrasekaran A, Paul VK. When do newborns die? A systematic review of timing of overall and cause-specific neonatal deaths in developing countries. Journal of perinatology: official journal of the California Perinatal Association. 2016;36 Suppl 1(Suppl 1):S1-s11. Epub 2016/04/26. doi: 10.1038/jp.2016.27. PubMed PMID: 27109087; PubMed Central PMCID: PMCPMC4848744.
- 11. Hofmeyr GJ, Black RE, Rogozińska E, Heuer A, Walker N, Ashorn P, et al. Evidence-based antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes. Lancet (London, England). 2023;401(10389):1733-44. Epub 2023/05/12. doi: 10.1016/s0140-6736(23)00355-0. PubMed PMID: 37167988.

- 12. Bhutta ZA, Das JK, Bahl R, Lawn JE, Salam RA, Paul VK, et al. Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost? Lancet (London, England). 2014;384(9940):347-70. Epub 2014/05/24. doi: 10.1016/s0140-6736(14)60792-3. PubMed PMID: 24853604.
- 13. Jobe AH, Kemp MW, Kamath-Rayne B, Schmidt AF. Antenatal corticosteroids for low and middle income countries. Semin Perinatol. 2019;43(5):241-6. Epub 2019/04/14. doi: 10.1053/j.semperi.2019.03.012. PubMed PMID: 30979597.
- 14. Sultana S, Vogel JP, Oladapo OT. The efficacy of antenatal corticosteroids to improve preterm newborn outcomes in low-resource countries: Are we there yet? BJOG: an international journal of obstetrics and gynaecology. 2023. Epub 2023/08/02. doi: 10.1111/1471-0528.17611. PubMed PMID: 37530472.
- 15. Vogel JP, Oladapo OT, Pileggi-Castro C, Adejuyigbe EA, Althabe F, Ariff S, et al. Antenatal corticosteroids for women at risk of imminent preterm birth in low-resource countries: the case for equipoise and the need for efficacy trials. BMJ Glob Health. 2017;2(3):e000398. Epub 2017/10/31. doi: 10.1136/bmjgh-2017-000398. PubMed PMID: 29082019; PubMed Central PMCID: PMCPMC5656119.
- 16. McClure EM, Goldenberg RL, Jobe AH, Miodovnik M, Koso-Thomas M, Buekens P, et al. Reducing neonatal mortality associated with preterm birth: gaps in knowledge of the impact of antenatal corticosteroids on preterm birth outcomes in low-middle income countries. Reprod Health. 2016;13(1):61. Epub 2016/05/26. doi: 10.1186/s12978-016-0180-6. PubMed PMID: 27221397; PubMed Central PMCID: PMCPMC4877818.
- Townsend R, Calvert C. Antenatal corticosteroids in adequately equipped facilities in low-resource settings. The Lancet Global health. 2022;10(10):e1379-e80. Epub 2022/09/17. doi: 10.1016/s2214-109x(22)00387-4. PubMed PMID: 36113517.
- 18. Azad K, Costello A. Extreme caution is needed before scale-up of antenatal corticosteroids to reduce preterm deaths in low-income settings. The Lancet Global health. 2014;2(4):e191-2. Epub 2014/08/12. doi: 10.1016/s2214-109x(14)70020-8. PubMed PMID: 25103050.
- 19. Ninan K, Liyanage SK, Murphy KE, Asztalos EV, McDonald SD. Evaluation of Long-term Outcomes Associated With Preterm Exposure to Antenatal Corticosteroids: A Systematic Review and Meta-analysis. JAMA pediatrics. 2022;176(6):e220483. Epub 2022/04/12. doi: 10.1001/jamapediatrics.2022.0483. PubMed PMID: 35404395; PubMed Central PMCID: PMCPMC9002717.
- 20. Lin YH, Lin CH, Lin MC, Hsu YC, Hsu CT. Antenatal Corticosteroid Exposure Is Associated with Childhood Mental Disorders in Late Preterm and Term Infants. J Pediatr. 2022. Epub 2022/10/07. doi: 10.1016/j.jpeds.2022.09.050. PubMed PMID: 36202238.
- 21. Raikkonen K, Gissler M, Kajantie E. Associations Between Maternal Antenatal Corticosteroid Treatment and Mental and Behavioral Disorders in Children. JAMA. 2020;323(19):1924-33. Epub 2020/05/20. doi: 10.1001/jama.2020.3937. PubMed PMID: 32427304; PubMed Central PMCID: PMCPMC7237984.
- 22. Kankaria A, Duggal M, Chauhan A, Sarkar D, Dalpath S, Kumar A, et al. Readiness to Provide Antenatal Corticosteroids for Threatened Preterm Birth in Public Health Facilities in Northern India. Global health, science and practice. 2021;9(3):575-89. Epub 2021/10/02. doi: 10.9745/ghsp-d-20-00716. PubMed PMID: 34593583; PubMed Central PMCID: PMCPMC8514043.
- Leslie HH, Spiegelman D, Zhou X, Kruk ME. Service readiness of health facilities in Bangladesh, Haiti, Kenya, Malawi, Namibia, Nepal, Rwanda, Senegal, Uganda and the United Republic of Tanzania. Bulletin of the World Health Organization. 2017;95(11):738-48. Epub 2017/11/18. doi: 10.2471/blt.17.191916. PubMed PMID: 29147054; PubMed Central PMCID: PMCPMC5677617.
- 24. The DHS program. The Demographic and Health Surveys, The Service Provision Assessment USAID; [cited 2023 July 20]. Available from: <a href="https://dhsprogram.com/methodology/Survey-Types/SPA.cfm">https://dhsprogram.com/methodology/Survey-Types/SPA.cfm</a>.

- 25. The World Health Organization. WHO recommendations on interventions to improve preterm birth outcomes. 2015
- 26. Ministry of Health, ICF. Nepal Health Facility Survey 2021. Kathmandu, Nepal, Rockville, Maryland, USA: Ministry of Health and Population, New ERA and ICF, 2022.
- 27. Ethiopian Public Health Institute, Ministry of Health E, ICF. Ethiopia Service Provision Assessment 2021-22. 2021.
- 28. National Institute of Population Research, Ministry of Health, ICF. Bangladesh Health Facility Survey 2017. Dhaka, Bangladesh: NIPORT ICF, 2020.
- 29. Agence Nationale de la Statistique et de la Démographie/ANSD, ICF. Senegal: Enquête Continue sur la Prestation des Services de Soins de Santé (ECPSS) 2018. Dakar, Sénégal: ANSD/ICF, 2020.
- 30. Agence Nationale de la Statistique et de la Démographie, ICF. Senegal: Enquête Continue sur la Prestation des Services de Soins de Santé (ECPSS) 2019. Dakar, Sénégal: ANSD/ICF, 2020.
- 31. Ecole de Santé Publique de Kishasa ESPK/Kinshasa RDdC, ICF. Republique Democratique du Congo Évaluation des Presentations des Services de souns de Santé EPSS 2017-2018. Kinshasa, République Démocratique du Congo: ESPK and ICF, 2019.
- 32. Ministry of Health Tanzania, National Bureau of Statistics Tanzania, Office of Chief Government Statistician/Tanzania, ICF International. Tanzania Service Provision Assessment Survey 2014-2015. Dar es Salaam, Tanzania: MoHSW/Tanzania, MoH/Tanzania, NBS/Tanzania, OCGS/Tanzania, and ICF International, 2016.
- 33. Ministry of Health MoH/Malawi, ICF International. Malawi Service Provision Assessment 2013-14. Lilongwe, Malawi: MoH/Malawi and ICF International, 2014.
- 34. The World Bank. The World Bank Microdata Library. Service Provision Assessment Survey Afghanistan 2018-2019 Available from: <a href="https://microdata.worldbank.org/index.php/catalog/3645/study-description">https://microdata.worldbank.org/index.php/catalog/3645/study-description</a>.
- 35. Institut Haïtien de l'Enfance , ICF. Haiti Évaluation de la Prestation des Services de Soins de Santé (EPSSS 2017-2018). 2019.
- 36. The DHS program. Continuous Service Provision Assessment.
- 37. Mallick L, Temsah G, Wang W. Comparing summary measures of quality of care for family planning in Haiti, Malawi, and Tanzania. PLOS ONE. 2019;14(6):e0217547. doi: 10.1371/journal.pone.0217547.
- 38. Sheffel A, Zeger S, Heidkamp R, Munos MK. Development of summary indices of antenatal care service quality in Haiti, Malawi and Tanzania. BMJ Open. 2019;9(12):e032558. doi: 10.1136/bmjopen-2019-032558.
- 39. The World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience. 2016.
- 40. Berrueta M, Hemingway-Foday J, Thorsten VR, Goldenberg RL, Carlo WA, Garces A, et al. Use of antenatal corticosteroids at health facilities and communities in low-and-middle income countries. Reprod Health. 2016;13(1):66. Epub 2016/05/28. doi: 10.1186/s12978-016-0176-2. PubMed PMID: 27228986; PubMed Central PMCID: PMCPMC4882797.
- 41. Vogel JP, Souza JP, Gülmezoglu AM, Mori R, Lumbiganon P, Qureshi Z, et al. Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health. Lancet (London, England). 2014;384(9957):1869-77. Epub 2014/08/17. doi: 10.1016/s0140-6736(14)60580-8. PubMed PMID: 25128271.
- 42. Riganti AA, Cafferata ML, Althabe F, Gibbons L, Segarra JO, Sandoval X, et al. Use of prenatal corticosteroids for preterm birth in three Latin American countries. Int J Gynaecol Obstet. 2010;108(1):52-7. Epub 2009/11/07. doi: 10.1016/j.ijgo.2009.08.022. PubMed PMID: 19892349; PubMed Central PMCID: PMCPMC3401047.

- Pattanittum P, Ewens MR, Laopaiboon M, Lumbiganon P, McDonald SJ, Crowther CA. Use of antenatal corticosteroids prior to preterm birth in four South East Asian countries within the SEA-ORCHID project. BMC pregnancy and childbirth. 2008;8:47. Epub 2008/10/18. doi: 10.1186/1471-2393-8-47. PubMed PMID: 18925968; PubMed Central PMCID: PMCPMC2596081.
- 44. Krauss Silva L PT, Franklin R, Oliveira N. Assessment of quality of obstetric care and corticoid use in preterm labor. Cadernos de Salude Publica. 1999;15(4):1-23.
- Tita AT, Selwyn BJ, Waller DK, Kapadia AS, Dongmo S. Evidence-based reproductive health care in Cameroon: population-based study of awareness, use and barriers. Bulletin of the World Health Organization. 2005;83(12):895-903. Epub 2006/02/08. PubMed PMID: 16462981; PubMed Central PMCID: PMCPMC2626486.
- 46. The World Health Organization. The WHO Model List of Essential Medicines. 2023.
- 47. Althabe F, Belizán JM, McClure EM, Hemingway-Foday J, Berrueta M, Mazzoni A, et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. The Lancet. 2015;385(9968):629-39. doi: 10.1016/s0140-6736(14)61651-2.
- 48. Collaborators WAT, Oladapo OT, Vogel JP, Piaggio G, Nguyen MH, Althabe F, et al. Antenatal Dexamethasone for Early Preterm Birth in Low-Resource Countries. N Engl J Med. 2020;383(26):2514-25. Epub 2020/10/24. doi: 10.1056/NEJMoa2022398. PubMed PMID: 33095526; PubMed Central PMCID: PMCPMC7660991.
- Zahroh RI, Hazfiarini A, Eddy KE, Vogel JP, Tunçalp ①, Minckas N, et al. Factors influencing appropriate use of interventions for management of women experiencing preterm birth: A mixed-methods systematic review and narrative synthesis. PLoS medicine. 2022;19(8):e1004074. doi: 10.1371/journal.pmed.1004074.
- Hall M, Valencia CM, Soma-Pillay P, Luyt K, Jacobsson B, Shennan A. Effective and simple interventions to improve outcomes for preterm infants worldwide: The FIGO PremPrep-5 initiative. Int J Gynaecol Obstet. 2024;165(3):929-35. Epub 2024/01/24. doi: 10.1002/ijgo.15269. PubMed PMID: 38264849.
- 51. Greensides D, Robb-McCord J, Noriega A, Litch JA. Antenatal Corticosteroids for Women at Risk of Imminent Preterm Birth in 7 sub-Saharan African Countries: A Policy and Implementation Landscape Analysis. Global health, science and practice. 2018;6(4):644-56. Epub 2018/12/24. doi: 10.9745/ghsp-d-18-00171. PubMed PMID: 30573455; PubMed Central PMCID: PMCPMC6370350.
- 52. Sebastian E, Bykersma C, Eggleston A, Eddy KE, Chim ST, Zahroh RI, et al. Cost-effectiveness of antenatal corticosteroids and tocolytic agents in the management of preterm birth: A systematic review. EClinicalMedicine. 2022;49:101496. Epub 2022/06/25. doi: 10.1016/j.eclinm.2022.101496. PubMed PMID: 35747187; PubMed Central PMCID: PMCPMC9167884.
- Eddy KE, Vogel JP, Scott N, Fetene D, Tidhar T, Oladapo OT, et al. Antenatal dexamethasone for improving preterm newborn outcomes in low-resource countries: a cost-effectiveness analysis of the WHO ACTION-I trial. The Lancet Global Health. 2022;10(10):e1523-e33. doi: 10.1016/s2214-109x(22)00340-0.
- 54. Bill and Melinda Gates Foundation. 2023 Goalkeepers Report. 2023.
- 55. The United Nations Population Fund. UN Commission on Life-Saving Commodities for Women and Children Commissioners' Report. 2012.
- Norman J, Shennan A, Jacobsson B, Stock SJ. FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm. Int J Gynaecol Obstet. 2021;155(1):26-30. Epub 2021/09/15. doi: 10.1002/ijgo.13836. PubMed PMID: 34520057.

## Figure legends

- Figure 1a. Utilization of antenatal corticosteroids by country
- Figure 1b. Utilization of antenatal corticosteroids by country and facility level
- **Figure 1c.** Availability of at least one valid corticosteroid by country
- **Figure 1d.** Availability of at least one valid corticosteroid by country and facility level
- Figure 2. Facility readiness by country, readiness category, and facility level
- Figure 3a. Corticosteroid availability versus ACS utilization by region
- Figure 3b. Overall readiness indices versus ACS utilization by region

Table 1. Characteristics of surveys and facilities included in the study

Country	Survey year	Number of facilities surveyed <sup>1</sup>	Number of facilities included in the analysis <sup>2</sup>	Urban location		Facility type	
					Level 1: Facilities that provide antenatal care	Level 2: Facilities that perform normal delivery	Level 3: Facilities that perform Cesarean section
		<b>N = 9793</b> Median 1158 (range 142 - 1576)	<b>N = 8669</b> Median 929 (range 108 - 1500)	Median 22.6% <sup>3</sup> (range 7.1% - 88.7%) <sup>3</sup>	Median 32.0% <sup>3</sup> (range 1.9% - 76.2%) <sup>3</sup>	Median 59.4% <sup>3</sup> (range 19.5% - 83.3%) <sup>3</sup>	Median 6.2% <sup>3</sup> (range 2.7% - 26.5%) <sup>3</sup>
South Asia							
Afghanistan	2018-2019	142	108	107 (99.4%)	7 (4.1%)	10 (10.1%)	91 (85.9%)
Bangladesh	2017-2018	1524	1498	379 (7.1%)	676 (76.2%)	551 (19.5%)	271 (4.4%)
Nepal	2021	1576	1500	961 (53.2%)	693 (47.5%)	565 (47.1%)	242 (5.3%)
Caribbean							
Haiti	2017-2018	1007	929	340 (36.5%)	567 (61.0%)	255 (27.5%)	107 (11.5%)
Sub-Saharar	ı Africa						
DRC	2017-2018	1380	1364	297 (22.0%)	10 (1.9%)	511 (71.6%)	843 (26.5%)
Ethiopia	2021-2022	1158	911	455 (18.2%)	261 (75.0%)	309 (22.3%)	341 (2.7%)
Malawi	2013-2014	977	645	119 (18.6%)	103 (16.5%)	471 (72.6%)	71 (10.9%)
Senegal	2018 and 2019	841	658	594 (88.7%)	65 (14.3%)	531 (78.6%)	62 (7.1%)
Tanzania	2014-2015	1188	1056	325 (19.1%)	104 (11.5%)	681 (83.3%)	271 (5.2%)

<sup>&</sup>lt;sup>1</sup> A total of 625 facilities that were sampled had a sampling weight of zero, indicating non-response, refusal, or closure. Those facilities were not surveyed and were excluded.

<sup>&</sup>lt;sup>2</sup> Only facilities that provided either antenatal care, performed normal delivery or Cesarean section were included in the analysis.


The median and range were obtained across eight countries excluding Afghanistan because its survey used a remarkably different sampling strategy.

Figure 1a. Utilization of antenatal corticosteroids by country

Figure 1b. Utilization of antenatal corticosteroids by country and facility level


Figure 1c. Availability of at least one valid corticosteroid by country

Figure 1d. Availability of at least one valid corticosteroid by country and facility level




AFG18: Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017-2018; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 2021-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; T214; Tanzania 2014-2015

Figure 2. Facility readiness by country, readiness category, and facility level



AFG18: Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017-2018; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 20121-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015; median\*: median across eight countries, excluding AFG18

**Figure 3a.** Corticosteroid availability versus ACS utilization by region **Figure 3b.** Overall readiness indices versus ACS utilization by region



AFG18: Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 20121-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015

## Antenatal corticosteroids for pregnant women at risk of preterm labor in lowand middle-income countries: utilization and facility readiness

**Supplementary file** 

Contents		Page
Supplemental Table 1	Sampling strategies of included SPA surveys	3
<b>Supplemental Table 2</b>	The indicators used to assess facility readiness based on the 2022 WHO recommendations on ACS	4
Supplemental Table 3	Response rates and number of facilities included in the analysis for each survey	5
<b>Supplemental Table 4</b>	Facility structural readiness for 35 indicators by country and facility level	6
Supplemental Figure 1	Heatmap of facility readiness for all facilities by country	11
Supplemental Figure 2	Heatmap of facility readiness for level 1 facilities by country	12
Supplemental Figure 3	Heatmap of facility readiness for level 2 facilities by country	13
Supplemental Figure 4	Heatmap of facility readiness for level 3 facilities by country	14
Supplemental Figure 5	ACS utilization and corticosteroid availability facility level	15
Supplemental Figure 6	Differences in overall readiness indexes by antenatal corticosteroids utilization for all facilities	16
Supplemental Figure 7	Differences in overall readiness indexes by antenatal corticosteroids utilization for level 2 facilities	17
<b>Supplemental Figure 8</b>	Differences in overall readiness indexes by antenatal corticosteroids utilization for level 3 facilities	18

## **Supplemental Table 1.** Sampling strategies of included SPA surveys

Survey	Sampling strategy
Afghanistan 2018-2019	The survey focused on major public and private hospitals in the main seven provinces (including Nangarhar, Paktya, Kunduz,
	Balkh, Kandahar, and Herat, and Kabul) in the country. Among six provinces excluding Kabul, all 12 public hospitals, 37
	private hospitals, and 52 private clinics were included. In Kabul, all 26 public and 20 private hospitals were surveyed, but a
	randomly selected sample of 13 private clinics (out of 84) were included.
Bangladesh 2017-2018	The survey adopted a stratified random sampling strategy for 1,600 facilities to obtain nationally representative data for
	different facility types, different facility management authorities, and each of the eight divisions (Barisal, Chittagong, Dhaka,
	Khulna, Mymensingh, Rajshahi, Rangpur, and Sylhet) of the country.
Nepal 2021	The survey adopted a stratified random sampling strategy for 1,633 health facilities through an equal probability systematic
	sampling. All government hospitals, all non-government hospitals with at least one bed, and all non-government hospitals in
	the provinces of Karnali and Sudurpashchim were included because of their small numbers. Also, all primary health care
	centers (PHCCs) and stand-alone HIV testing and counseling centers (stand-alone HTCs) were included.
Haiti 2017-2018	The survey was a national census of all operational health facilities in the country during the survey period of 2017 to 2018.
Demographic Republic of	The survey adopted a probability sampling strategy from 12,059 health facilities in the country, excluding health posts. On
Congo 2017-2018	average, approximately 50 facilities were selected for each of the 26 provinces, reaching a sample of 1,380 facilities.
Ethiopia 2021-2022	The survey adopted a stratified random sampling strategy reaching a sample of 1,407 health facilities via an unequal
	probability systematic sampling. Within each region, stratification was achieved by facility type. All public and private
	hospitals were included because of their small numbers and crucial roles in the country's health system. Health centers were
	sampled but all health centers in Dire Dawa and Harari were included. Clinics were sampled with all higher clinics included
	and all clinics in Harari included. Health posts were sampled.
Malawi 2013-2014	The survey was a national census of all formal-sector health facilities, including public, private and other managing authority
	types, in the country during the survey period between 2013 to 2014.
Senegal 2018 and 2019	Senegal implemented a continuous SPA, which was designed to continuously collect data on health facilities over a period of 5
	years from 2012 to 2017, aiming to survey all health facilities in the country.
Tanzania 2014-2015	The survey was a sample of formal-sector health facilities, including public and private, during the survey period between 2014
	to 2015. The sample was selected to obtain national representative data by facility type, managing authority type, and regions.

# **Supplemental Table 2.** The indicators used to assess facility readiness based on the 2022 WHO recommendations on ACS use

Antenatal corticosteroid therapy is recommended for women with a high likelihood of preterm birth from 24 weeks to 34 weeks of gestation when the following conditions (1 to 5) are met:

WHO conditions/criteria	Readiness categories	Indica	SPA dataset		
Gestational age assessment can be accurately undertaken.      There is a high likelihood of preterm birth within 7 days of starting therapy.	Readiness to accurately assess GA and identify high likelihoods of preterm labor	Equipment	ultrasound	Inventory dataset	
3. There is no clinical evidence of maternal infection.	Readiness to identify maternal infections	Equipment Diagnostics	thermometer hematology analyzer HIV rapid diagnostic test syphilis rapid diagnostic test	-	
4. Adequate childbirth care is available (including capacity to recognize and safely manage preterm labor and birth).	Readiness to provide adequate childbirth care	Equipment	delivery pack cord clamp manual vacuum extractor vacuum aspiration kit or D&C kit forceps (large) forceps (medium)		
		Medicines and commodities Staff and guidelines	parenteral antibiotics parenteral anticonvulsants (diazepam) parenteral oxytocin a health worker who can perform C/S an anesthetist national guidelines for BEmONC national guidelines for CEmONC		
5. The preterm newborn can receive adequate care (including resuscitation, kangaroo mother care, thermal care, feeding support, infection treatment and respiratory support including continuous positive airway pressure as needed).	Readiness to provide preterm newborn care	Equipment	suction bulb or penguin sucker stethoscope newborn masks (0, 1), neonatal size self-inflating bag incubator other external heat source pulse oximeter oxygen concentrator filled oxygen cylinder oxygen distribution system		
		Medicines and commodities Staff and guidelines	glucometer glucometer strips hand-washing soap disposable latex gloves staff trained on integrated Management of Pregnancy and Childbirth (IMPAC) staff trained on Comprehensive Emergency Obstetric and Newborn Care	Health worker interview dataset <sup>1</sup>	
			staff trained on routine care for labor and normal vaginal delivery guidelines on management of preterm labor	Inventory dataset	

<sup>\*</sup>GA: gestational age; C/S Cesarean section; BEmONC: Basic Emergency Obstetrics and Newborn Care; CEmONC: Comprehensive Emergency Obstetrics and Newborn Care

<sup>&</sup>lt;sup>1</sup> To report readiness at the facility level when using data from health worker interview, we converted data from health worker level to facility level by measuring the facility with at least one health worker who had received relevant training.

**Supplemental Table 3.** Survey response rates and number of facilities sampled, surveyed, and included in the analysis

Country	Survey year	Response rate <sup>1</sup>	Number of facilities sampled	Number of facilities surveyed <sup>4</sup>	Number (%) of facilities included in the analysis <sup>5</sup>
		median 94.9% (range 88.8%, 99.0%)	N =10418 median 1130 (range 160, 1626)	<b>N</b> = <b>9793</b> median 1158 (range 142, 1576)	<b>N = 8669</b> median 929 (range 108, 1500)
South Asia					
Afghanistan	2018-19	88.8%2	160	142	108 (76.1%)
Bangladesh	2017-18	95.3%	1600	1524	1498 (98.3%)
Nepal	2021	97.0%	1626	1576	1500 (95.2%)
Caribbean					
Haiti	2017-18	97.5%	1033	1007	929 (92.3%)
Sub-Saharar	Africa				
DRC	2017-18	97.7%	1412	1380	1364 (98.8%)
Ethiopia	2021-22	82.3%	1407	1158	911 (78.7%)
Malawi	2013-14	92.2%	1060	977	645 (66.1%)
Senegal	2018	89.3%	466	841	601 (71 50/)
Senegal	2019	94.5% <sup>3</sup>	454	(2018: 416; 2019: 425)	601 (71.5%)
Tanzania	2014-15	99.0%	1200	1188	1056 (88.9%)

<sup>&</sup>lt;sup>1</sup> Response rates were obtained from SPA final reports.

<sup>&</sup>lt;sup>2</sup> Afghanistan 2018-2019 survey does not have a publicly available SPA final report. Its response rate was manually calculated.
<sup>3</sup> The response rate for Senegal 2019 from its final report is 94.5%, calculated by excluding health huts. The rate is 93.6% (425/454) if including health huts.

<sup>&</sup>lt;sup>4</sup> The numbers of facilities surveyed are smaller than the numbers of facilities sampled because of non-response, refusal, or closure.

<sup>&</sup>lt;sup>5</sup> Facilities included in the analysis are facilities that either provided antenatal care, performed normal delivery, or performed Cesarean sections. The proportion was calculated by dividing the number of facilities included in the analysis by the number of facilities surveyed.

Four readiness categories based				South Asia Afghanistan 2018-19 Bangladesh 2017-18								
on five WHO		The proportion of facilities	s with the indicators available		Afghanistan 2018-19					_		
criteria				Median (range) <sup>1</sup>	Overall	Level 1	Level 2	Level 3	Overall	Level 1	Level 2	Level 3
1. Assess GA accurately and identify imminent preterm labor	Equipment	The proportion of facilities	with a functional ultrasound machine in use	7.3% (0.2%, 12.3%)	92(82.4%)	3(41.2%)	5(67%)	84(86.2%)	178(3.6%)	13(0.7%)	19(1.7%)	92(82.4%)
. Identify naternal nfections	Equipment	The proportion of facilities with this equipment	thermometer	52.3% (20.7%, 76.2%)	65(58.6%)	0(0%)	6(75%)	59(59.4%)	734(20.7%)	0(0%)	481(85.2%)	65(58.6%
	Diagnostics	The proportion of	(1) hematology analyzer	7.6% (2.7%, 30.5%)	94(92%)	6(86.3%)	5(70.1%)	83(94.8%)	131(2.7%)	11(0.5%)	16(1.7%)	94(92%
		facilities with the	(2) HIV rapid diagnostic test	52.4% (21.2%, 82.1%)	37(25.8%)	2(27.5%)	1(7.2%)	34(27.9%)				37(25.89
		following diagnostics	(3) syphilis rapid diagnostic test	13.8% (3.0%, 68.8%)	30(21.9%)	2(27.5%)	1(7.2%)	27(23.3%)	128(3%)	18(1.1%)	22(2.7%)	30(21.9
. Provide	Equipment	The proportion of	(1) delivery pack	62.5% (19.0%, 87.5%)	80(74.5%)	0(0%)	5(28.6%)	75(83.4%)	692(19%)	0(0%)	449(77.5%)	80(74.5
dequate		facilities with the	(2) cord clamp	55.8% (15.8%, 82.1%)	78(70.3%)	0(0%)	6(37.3%)	72(77.5%)	566(15.8%)	0(0%)	358(63.6%)	78(70.3
hildbirth care		following equipment to perform CEmONC	(3) manual vacuum extractor	9.1% (4.7%, 33.9%)	76(69.1%)	0(0%)	3(17.4%)	73(78.4%)	214(4.8%)	0(0%)	90(14.7%)	76(69.1
		(obstetric related)	(4) vacuum aspiration kit or D&C kit	10.9% (5.8%, 49.4%)	74(60.5%)	0(0%)	6(37%)	68(66.1%)	303(5.8%)	0(0%)	125(14.5%)	74(60.5
		(,	(5) forceps (large)	32.2% (5.4%, 73.5%)	85(74.9%)	0(0%)	10(100%)	75(75.6%)	718(19.7%)	0(0%)	473(80.4%)	85(74.9
			(6) forceps (medium)	34.8% (5.2%, 82.2%)	84(74.3%)	0(0%)	10(100%)	74(74.8%)	697(19.4%)	0(0%)	451(79.4%)	84(74.3
	Medicines	The proportion of	(1) parenteral antibiotics	31.4% (4.6%, 51.3%)	45(42%)	0(0%)	2(50%)	43(43%)	281(4.6%)	0(0%)	82(7.6%)	45(429
	and	facilities with the	(2) parenteral anticonvulsants (diazepam)	31.8% (4.7%, 66.6%)	49(45.1%)	0(0%)	2(50%)	47(46.7%)	264(4.7%)	0(0%)	73(8.6%)	49(45.1
	commodities	following medicines	(3) parenteral oxytocin	56.4% (7.5%, 79.2%)	78(74.4%)	0(0%)	5(32.2%)	73(82.8%)	401(7.5%)	0(0%)	178(21.6%)	78(74.4
	Staff and	The proportion of	(1) a health worker who can perform C/S	4.0% (2.2%, 20.5%)	46(32.5%)	0(0%)	0(0%)	46(37.8%)	158(2.5%)	0(0%)	0(0%)	46(32.5
	guidelines	facilities that has the	(2) an anesthetist	3.8% (1.9%, 12.3%)	36(26.6%)	0(0%)	0(0%)	36(31%)	118(1.9%)	0(0%)	0(0%)	36(26.6
		following staff The proportion of	(1) national guidelines for BEmONC	, , , ,		` '	` ′			` '	` '	
		facilities with the	(2) national guidelines for CEmONC	18.2% (2.8%, 40.9%)	9(5.1%)	0(0%)	0(0%)	9(5.9%)	132(2.8%)	0(0%)	80(10.9%)	9(5.19
		following guidelines	., ,	13.4% (2.2%, 41.9%)	9(5.1%)	0(0%)	0(0%)	9(5.9%)	114(2.2%)	0(0%)	65(8.7%)	9(5.1%
. Provide	Equipment	The proportion of	(1) suction bulb or penguin sucker	46.2% (15.8%, 80.4%)	78(81.6%)	0(0%)	7(79.4%)	71(85.7%)	652(15.8%)	0(0%)	414(62.6%)	78(81.6
dequate preterm ewborn care		facilities with the following equipment for	(2) stethoscope (in general)	51.1% (23.1%, 81.3%)	87(87.4%)	0(0%)	5(69.7%)	82(93.7%)	804(23.2%)	0(0%)	540(97.6%)	87(87.4
ewborn care		neonatal resuscitation	(3) newborn masks, neonatal size self- inflating bag	37.3% (13.1%, 74.4%)	83(77.3%)	0(0%)	6(37%)	77(85.7%)	601(13.1%)	0(0%)	358(48%)	83(77.3
		The proportion of facilities with equipment	(1) incubator	4.5% (2.2%, 6.6%)	54(55.4%)	0(0%)	2(11.1%)	52(63.3%)	127(2.2%)	0(0%)	29(2.7%)	54(55.4
		for thermal care	(2) other external heat source	14.6% (4.2%, 58.4%)	68(64.1%)	0(0%)	3(16.7%)	65(72.7%)	176(4.2%)	0(0%)	61(10.7%)	68(64.1
		The proportion of	(1) pulse oximeter	8.8% (2.8%, 42.0%)	49(53.7%)	1(13.7%)	1(5.6%)	47(61.2%)	142(3%)	7(0.4%)	18(1.1%)	49(53.7
		facilities with equipment	(2) oxygen concentrator	9.2% (2.4%, 15.2%)	40(48.2%)	0(0%)	0(0%)	40(56.1%)	192(3.2%)	6(0.3%)	69(5.8%)	40(48.2
		for respiratory care, including safe oxygen use	(3) filled oxygen cylinder	9.8% (1.8%, 22.5%)	82(84.9%)	3(45.1%)	7(82.4%)	72(87.1%)	334(6.6%)	23(1%)	122(13.2%)	82(84.9
		including sale oxygen use	(4) oxygen distribution system	3.5% (1.6%, 8.5%)	16(13.3%)	2(27.5%)	1(5.6%)	13(13.5%)	84(1.6%)	2(0.1%)	26(2%)	16(13.3
	Medicines	The proportion of	(1) glucometer	22.2% (19.3%, 79.7%)	42(37%)	0(0%)	3(55.5%)	39(36.6%)	310(21.1%)	124(21.7%)	64(10.6%)	42(379
	and commodities	facilities with commodities for monitoring blood glucose	(2) glucometer strips	20.6% (17.4%, 82.0%)	37(34%)	0(0%)	3(55.5%)	34(33.1%)	303(21.3%)	126(22.2%)	57(9.9%)	37(349
		The proportion of facilities with medicines	(1) hand-washing soap	50.8% (45.3%, 88.5%)	71(62.6%)	7(100%)	4(22.7%)	60(65.5%)	1075(72.8%)	473(72.1%)	406(77.3%)	71(62.6
		and commodities for infection management	(2) disposable latex gloves	89.8% (69.4%, 96.4%)	102(88.9%)	7(100%)	8(50.5%)	87(92.9%)	1158(73.7%)	458(70.3%)	472(84.7%)	102(88.
	Staff and guidelines	The proportion of facilities with at least one	(1) Integrated Management of Pregnancy and Childbirth (IMPAC)	18.6% (2.4%, 37.8%)	15(12.9%)	1(13.7%)	0(0%)	14(14.3%)	116(15%)	32(16.6%)	45(11.7%)	15(12.9
		health worker who has received training about	(2) Comprehensive Emergency Obstetric and Newborn Care (CEMONC)	17.6% (2.0%, 29.6%)	7(4.2%)	0(0%)	0(0%)	7(4.9%)	84(10.6%)	19(12.3%)	32(6.1%)	7(4.2%
		the following in the past 24 months The proportion of	(3) Routine care for labor and normal vaginal delivery guidelines on management of preterm labor	24.0% (2.8%, 43.5%)	16(13.5%)	1(13.7%)	0(0%)	15(15.1%)	153(18.2%)	32(20.5%)	78(14.8%)	16(13.5)
		facilities with the following guidelines		10.2% (3.2%, 34.7%)	9(5.1%)	0(0%)	0(0%)	9(5.9%)	140(3.2%)	0(0%)	85(13.6%)	9(5.1%

<sup>&</sup>lt;sup>1</sup>Median and range were obtained from data across 8 countries (excluding Afghanistan).

<sup>\* :</sup> data unavailable

Four readiness categories based on five WHO		The proportion of facil		<b>South Asia</b> Nepal 2021			<b>Caribbean</b> Haiti 2017-2018				
on five WHO criteria				Overall	Level 1	Level 2	Level 3	Overall	Level 1	Level 2	Level 3
1. Assess GA accurately and identify imminent preterm labor	Equipment	The proportion of facilities with	a functional ultrasound machine in use	422(12.3%)	61(5.3%)	135(10.3%)	226(93.3%)	100(10.8%)	18(3.2%)	14(5.5%)	68(63.5%)
2. Identify maternal	Equipment	The proportion of facilities with this equipment	thermometer	731(48%)	0(0%)	515(91.7%)	216(90.1%)	310(33.4%)	0(0%)	227(89%)	83(77.5%)
infections	Diagnostics	The proportion of facilities with the following diagnostics	(1) hematology analyzer     (2) HIV rapid diagnostic test     (3) syphilis rapid diagnostic test	309(8.6%)	37(3.8%) 69(7.2%)	70(5.4%) 149(16.2%)	202(79.3%) 86(32.4%)	283(30.5%) 197(21.2%) 194(20.9%)	123(21.7%) 97(17.1%) 106(18.7%)	88(34.5%) 68(26.6%) 60(23.5%)	72(67.3%) 32(29.9%) 28(26.2%)
3. Provide adequate childbirth care	Equipment	The proportion of facilities with the following equipment to perform CEmONC (obstetric related)	(1) delivery pack (2) cord clamp (3) manual vacuum extractor (4) vacuum aspiration kit or D&C kit	767(50.6%) 714(46.8%) 313(12.1%) 326(10.9%)	0(0%) 0(0%) 0(0%) 0(0%)	549(97.2%) 505(89.4%) 137(17.6%) 138(14.5%)	218(88.6%) 209(87.1%) 176(70.8%) 188(76.6%)	283(30.5%) 314(33.8%) 51(5.5%) 100(10.8%)	0(0%) 0(0%) 0(0%) 0(0%)	198(77.6%) 218(85.5%) 20(7.8%) 55(21.6%)	85(79.4%) 96(89.6%) 31(28.9%) 45(42%)
	Medicines and commodities	The proportion of facilities with the following medicines	(5) forceps (large) (6) forceps (medium) (1) parenteral antibiotics (2) parenteral anticonvulsants (diazepam) (3) parenteral oxytocin	640(40.6%) 707(46.1%) 575(34.4%) 358(14.7%) 760(50.5%)	0(0%) 0(0%) 0(0%) 0(0%) 0(0%)	441(76.7%) 499(88%) 388(64%) 175(22.4%) 547(97.4%)	199(83.9%) 208(87.1%) 187(79%) 183(76.8%) 213(86.7%)	50(5.4%) 49(5.3%) 179(19.3%) 112(12.1%) 257(27.7%)	0(0%) 0(0%) 0(0%) 0(0%) 0(0%)	17(6.7%) 20(7.9%) 109(42.8%) 67(26.3%) 173(67.9%)	33(30.8%) 29(27.1%) 70(65.3%) 45(41.9%) 84(78.4%)
	Staff and guidelines	The proportion of facilities that has the following staff The proportion of facilities	(1) a health worker who can perform C/S (2) an anesthetist (1) national guidelines for BEmONC	166(3.5%) 152(3.2%)	0(0%) 0(0%)	0(0%) 0(0%)	166(65.6%) 152(60.4%)	54(5.8%) 43(4.6%)	0(0%) 0(0%)	0(0%) 0(0%)	54(50.4%) 43(40.1%)
		with the following guidelines	(2) national guidelines for CEmONC					124(13.4%)	0(0%)	88(34.5%)	36(33.6%)
4. Provide adequate preterm newborn care	Equipment	The proportion of facilities with the following equipment for neonatal resuscitation	(1) suction bulb or penguin sucker     (2) stethoscope (in general)     (3) newborn masks, neonatal size self-inflating bag	393(22.3%) 771(51.1%) 718(47.7%)	0(0%) 0(0%) 0(0%)	252(40.4%) 551(98%) 511(91.5%)	141(61.2%) 220(91.9%) 207(86.2%)	325(35%) 335(36.1%) 207(22.3%)	0(0%) 0(0%) 0(0%)	226(88.6%) 242(94.9%) 122(47.8%)	99(92.5%) 93(86.8%) 85(79.5%)
		The proportion of facilities with equipment for thermal care The proportion of facilities	(1) incubator (2) other external heat source (1) pulse oximeter	141(4.5%) 530(33.6%) 770(42%)	0(0%) 0(0%) 211(28.1%)	42(4.7%) 354(63.2%) 340(50.4%)	99(43.6%) 176(72.8%) 219(91.8%)	59(6.4%) 160(17.2%) 155(16.7%)	0(0%) 0(0%) 58(10.2%)	24(9.5%) 90(35.3%) 54(21.2%)	35(32.7%) 70(65.4%) 43(40.1%)
		with equipment for respiratory care, including safe oxygen use	(2) oxygen concentrator (3) filled oxygen cylinder (4) oxygen distribution system	307(11.7%) 507(22.5%) 128(3.2%)	37(4.1%) 85(8.5%) 11(1%)	145(14.7%) 237(30.3%) 7(0.6%)	125(52.3%) 185(78.7%) 110(45.4%)	100(10.8%) 149(16.1%) 32(3.5%)	23(4.1%) 36(6.3%) 5(0.9%)	40(15.7%) 55(21.7%) 11(4.4%)	37(34.6%) 58(54.2%) 16(14.9%)
	Medicines and	The proportion of facilities with commodities for	(1) glucometer	348(19.4%)	94(11.4%)	150(24.9%)	104(42.6%)	463(49.8%)	227(40%)	159(62.3%)	77(71.9%)
	commodities	monitoring blood glucose  The proportion of facilities	(2) glucometer strips (1) hand-washing soap	325(17.4%)	82(10%)	138(21.9%)	105(42.9%)	424(45.6%)	201(35.4%)	146(57.2%)	77(71.9%)
		with medicines and commodities for infection management	(2) disposable latex gloves	1297(88.5%) 1433(95.8%)	595(86.2%) 651(93.8%)	507(91.7%) 554(97.9%)	195(81.8%) 228(94.2%)	492(52.9%) 831(89.5%)	305(53.8%) 497(87.7%)	133(52.1%) 235(92.2%)	54(50.5%) 99(92.5%)
	Staff and guidelines	The proportion of facilities with at least one health worker who has received training about the following in the past 24 months	(1) Integrated Management of Pregnancy and Childbirth (IMPAC) (2) Comprehensive Emergency Obstetric and Newborn Care (CEmONC) (3) Routine care for labor and normal vaginal delivery	87(4.5%) 98(4.4%) 180(11.1%)	4(0.7%) 5(1.2%) 7(1%)	54(7.7%) 57(6.8%) 119(20.4%)	29(10.2%) 36(12.5%) 54(18.9%)	257(27.8%) 218(23.5%) 258(27.9%)	76(13.5%) 59(10.4%) 75(13.3%)	109(42.8%) 91(35.7%) 111(43.6%)	72(67.3%) 68(63.5%) 72(67.3%)
		The proportion of facilities with the following guidelines	guidelines on management of preterm labor					60(6.4%)	0(0%)	40(15.6%)	20(18.6%)

<sup>\* :</sup> data unavailable

Four readiness categories based							Sub-Saharan A	frica			
on five WHO		The proportion of facil	ities with the indicators available	0 11	DRC 2017			0 "	Ethiopia 2		
criteria				Overall	Level 1	Level 2	Level 3	Overall	Level 1	Level 2	Level 3
I. Assess GA accurately and dentify imminent preterm labor	Equipment	The proportion of facilities with	a functional ultrasound machine in use	450(10.7%)	1(12.5%)	8(1.2%)	441(36.2%)	344(4.5%)	16(1.2%)	38(6.1%)	290(84.9%)
2. Identify naternal	Equipment	The proportion of facilities with this equipment	thermometer	1102(76.2%)	0(0%)	377(74.6%)	725(85.9%)	568(21%)	0(0%)	262(83.5%)	306(91%)
nfections	Diagnostics	The proportion of facilities	(1) hematology analyzer	179(5.4%)	1(12.5%)	8(2%)	170(14.1%)	364(5.7%)	17(1%)	68(12.4%)	279(82.2%
		with the following diagnostics	(2) HIV rapid diagnostic test	654(44.2%)	4(28.1%)	189(39.3%)	461(58.5%)	616(29.1%)	62(10.5%)	258(85.6%)	296(80.1%
			(3) syphilis rapid diagnostic test	218(11.8%)	1(12.5%)	53(9.9%)	164(16.9%)	238(11.1%)	24(5.2%)	107(29.1%)	107(28.2%
. Provide	Equipment	The proportion of facilities	(1) delivery pack	1240(87.5%)	0(0%)	437(87.2%)	803(94.5%)	605(22.5%)	0(0%)	276(89.5%)	329(96.9%
dequate		with the following equipment to perform CEmONC	(2) cord clamp	1160(79.1%)	0(0%)	409(80.1%)	751(81.9%)	625(23.4%)	0(0%)	292(93.4%)	333(97.9%
hildbirth care		(obstetric related)	(3) manual vacuum extractor	273(7.2%)	0(0%)	28(5.1%)	245(13.4%)	518(16.5%)	0(0%)	205(62.8%)	313(92.8%
		(	(4) vacuum aspiration kit or D&C kit	729(36.4%)	0(0%)	134(26.4%)	595(65.9%)	385(10%)	0(0%)	124(36.2%)	261(70.4%
			(5) forceps (large)	127(5.9%)	0(0%)	31(5.4%)	96(7.6%)	617(23.9%)	0(0%)	286(95.4%)	331(97.4%
			(6) forceps (medium)	112(5.2%)	0(0%)	21(4.6%)	91(7.1%)	611(23.4%)	0(0%)	281(93.4%)	330(96.49
	Medicines	The proportion of facilities	(1) parenteral antibiotics	549(36.4%)	0(0%)	174(34.3%)	375(44.4%)	489(16.4%)	0(0%)	204(64.6%)	285(75.79
	and commodities	with the following medicines	(2) parenteral anticonvulsants (diazepam)	785(55.4%)	0(0%)	253(52.7%)	532(66.6%)	351(10.4%)	0(0%)	205(62.8%)	230(61.69
			(3) parenteral oxytocin	1110(77.3%)	0(0%)	394(77.5%)	716(82.4%)	611(22.8%)	0(0%)	283(90.7%)	328(96.7
	Staff and	The proportion of facilities	(1) a health worker who can perform C/S	725(20.5%)	0(0%)	0(0%)	725(77.3%)	312(2.2%)	0(0%)	0(0%)	312(83.5
	guidelines	that has the following staff	(2) an anesthetist	486(12.3%)	0(0%)	0(0%)	486(46.4%)	311(2.2%)	0(0%)		311(82.89
		The proportion of facilities	(1) national guidelines for BEmONC					350(11.5%)	0(0%)		203(55%
		with the following guidelines	(2) national guidelines for CEmONC	411(24.7%)	0(0%)	118(23.2%)	293(30.5%)	162(4.3%)	0(0%)	45(15.5%)	117(33%
Provide	Equipment	The proportion of facilities with the following equipment for neonatal resuscitation	(1) suction bulb or penguin sucker	1099(80.4%)	0(0%)	388(80%)	711(87.1%)	577(21.3%)	0(0%)		316(93.69
dequate preterm ewborn care			(2) stethoscope (in general)	1144(81.3%)	0(0%)	412(81.5%)	732(86.3%)	612(23.1%)	0(0%)		322(95.19
			(3) newborn masks, neonatal size self-inflating bag	561(26.9%)	0(0%)	102(21%)	459(44.6%)	593(21.6%)	0(0%)		331(97.49
		The proportion of facilities with equipment for thermal	(1) incubator	114(3%)	0(0%)	3(0.6%)	111(9.7%)	232(4.5%)	0(0%)	60(14.4%)	172(47.19
		care	(2) other external heat source	411(18.2%)	0(0%)	62(12.4%)	349(35.3%)	382(9.4%)	0(0%)	118(32.7%)	264(79.59
		The proportion of facilities	(1) pulse oximeter	78(2.8%)	1(12.5%)	2(0.4%)	75(8.6%)	318(26.8%)	23(31.1%)	85(21%)	210(64.9%
		with equipment for respiratory	(2) oxygen concentrator	105(2.4%)	2(14.4%)	2(0.5%)	101(6.7%)	184(11.2%)	11(11.3%)	38(6.8%)	135(46.59
		care, including safe oxygen use	(3) filled oxygen cylinder	73(1.8%)	2(14.4%)	1(0.3%)	70(4.8%)	200(13%)	12(15.7%)	43(7.9%)	145(49%
		ase	(4) oxygen distribution system					80(4.8%)	3(7.2%)	12(2.6%)	65(17.7%
	Medicines	The proportion of facilities	(1) glucometer	761(34%)	3(27.7%)	76(18.2%)	682(77%)	564(21%)	38(4.1%)	202(68.8%)	324(95.69
	and commodities	with commodities for monitoring blood glucose	(2) glucometer strips	674(29.6%)	3(27.7%)	63(15.6%)	608(67.4%)	542(19.3%)	35(3.8%)	188(62.5%)	319(94.49
		The proportion of facilities	(1) hand-washing soap	686(48.4%)	7(57.8%)	228(45.6%)	451(55.6%)	487(45.3%)	116(42.7%)	160(51.8%)	211(63.39
		with medicines and commodities for infection management	(2) disposable latex gloves	1256(90.2%)	10(100%)	453(88.5%)	793(93.9%)	761(69.4%)	160(61.5%)	283(93%)	318(94.19
	Staff and guidelines	The proportion of facilities with at least one health worker	(1) Integrated Management of Pregnancy and Childbirth (IMPAC)	423(34.5%)	1(41.7%)	107(33.8%)	315(35.6%)	108(2.4%)	5(0.4%)	41(6.6%)	62(24.7%
		who has received training about the following in the past	(2) Comprehensive Emergency Obstetric and Newborn Care (CEmONC)	401(29.6%)	1(41.7%)	93(28.6%)	307(31.2%)	112(2%)	4(0.3%)	38(5.6%)	70(19.3%
		24 months	(3) Routine care for labor and normal vaginal delivery	415(33.6%)	1(41.7%)	107(33.5%)	307(33.8%)	126(2.8%)	7(1.1%)	44(6.5%)	75(20.6%
		The proportion of facilities with the following guidelines	guidelines on management of preterm labor	232(11.4%)	0(0%)	46(8.8%)	186(19%)	248(7.2%)	0(0%)	86(27.1%)	162(43.29

<sup>\* :</sup> data unavailable

Four readiness categories based				Sub-Saharan Africa Malawi 2013-2014 Senegal 2018 and 2019							
on five WHO		The proportion of fac	cilities with the indicators available						Senegal 20		
criteria				Overall	Level 1	Level 2	Level 3	Overall	Level 1	Level 2	Level 3
I. Assess GA accurately and dentify imminent preterm labor	Equipment	The proportion of facilities with	a functional ultrasound machine in use	65(10%)	4(3.8%)	7(1.5%)	54(76%)	1(0.2%)	0(0%)	1(0.2%)	0(0%)
2. Identify naternal	Equipment	The proportion of facilities with this equipment	thermometer	453(69.6%)	0(0%)	390(82.6%)	63(88.6%)	495(69.9%)	0(0%)	436(80.2%)	59(96.4%
nfections	Diagnostics	The proportion of facilities	(1) hematology analyzer	57(8.8%)	8(7.7%)	6(1.3%)	43(60.8%)	139(16.1%)	7(28.9%)	80(10.5%)	52(52.2%
		with the following diagnostics	(2) HIV rapid diagnostic test	391(60.6%)	57(55.4%)	288(61.2%)	46(64.6%)	548(78.7%)	40(40.5%)	461(86.2%)	47(72.7%
			(3) syphilis rapid diagnostic test	96(14.8%)	17(16.4%)	54(11.4%)	25(35.2%)	487(68.8%)	37(39.5%)	410(77.6%)	40(30.2%
3. Provide	Equipment	The proportion of facilities	(1) delivery pack	486(74.8%)	0(0%)	418(88.7%)	68(95.7%)	579(83.7%)	0(0%)	521(97.8%)	58(96%
dequate		with the following equipment	(2) cord clamp	482(74.1%)	0(0%)	416(88.2%)	66(92.9%)	568(82.1%)	0(0%)	509(95.8%)	59(96.49
childbirth care		to perform CEmONC (obstetric related)	(3) manual vacuum extractor	221(33.9%)	0(0%)	165(34.8%)	56(78.8%)	96(11%)	0(0%)	57(7.6%)	39(71.59
		(obstetric related)	(4) vacuum aspiration kit or D&C kit	131(20.1%)	0(0%)	97(20.4%)	34(48%)	343(49.4%)	0(0%)	303(55.7%)	40(79.19
			(5) forceps (large)	448(69%)	0(0%)	390(82.8%)	58(81.7%)	521(73.5%)	0(0%)	464(85%)	57(94.99
			(6) forceps (medium)	434(66.9%)	0(0%)	379(80.5%)	55(77.5%)	533(75.6%)	0(0%)	474(87.5%)	59(96.49
	Medicines	The proportion of facilities	(1) parenteral antibiotics	299(46.1%)	0(0%)	244(51.9%)	55(77.4%)	362(51.3%)	0(0%)	316(60.7%)	46(51.19
	and	with the following medicines	(2) parenteral anticonvulsants (diazepam)	433(66.6%)	0(0%)	371(78.6%)	62(87.2%)	363(51.6%)	0(0%)	317(58.1%)	46(83.69
	commodities		(3) parenteral oxytocin	514(79.2%)	0(0%)	449(95.3%)	65(91.4%)	451(62.3%)	0(0%)	402(74.5%)	49(52.2
	Staff and	The proportion of facilities	(1) a health worker who can perform C/S	57(8.7%)	0(0%)	0(0%)	57(80.1%)	49(3.5%)	0(0%)	0(0%)	49(48.7
	guidelines	that has the following staff	(2) an anesthetist	47(7.2%)	0(0%)	0(0%)	47(66%)	51(3.6%)	0(0%)	0(0%)	51(50.4
		The proportion of facilities	(1) national guidelines for BEmONC	266(40.9%)	0(0%)	231(48.9%)	35(49.1%)				
		with the following guidelines	(2) national guidelines for CEmONC	148(22.8%)	0(0%)	117(24.8%)	31(43.6%)	304(41.9%)	0(0%)	269(47.5%)	35(64.59
. Provide	Equipment	The proportion of facilities with the following equipment	(1) suction bulb or penguin sucker	399(61.5%)	0(0%)	346(73.6%)	53(74.5%)	480(66.4%)	0(0%)	434(76.9%)	46(84.99
dequate preterm			(2) stethoscope (in general)	423(65.2%)	0(0%)	369(78.4%)	54(76.1%)	369(51.1%)	0(0%)	314(56.7%)	55(92.29
ewborn care		for neonatal resuscitation	(3) newborn masks, neonatal size self-inflating bag	483(74.4%)	0(0%)	418(88.7%)	65(91.4%)	477(67.4%)	0(0%)	419(77.1%)	58(94.99
		The proportion of facilities	(1) incubator	37(5.7%)	0(0%)	8(1.7%)	29(41.1%)	41(6.6%)	0(0%)	18(3%)	23(59.49
		with equipment for thermal care	(2) other external heat source	78(12%)	0(0%)	31(6.5%)	47(66.3%)	407(58.4%)	0(0%)	350(65.9%)	57(94.29
		The proportion of facilities	(1) pulse oximeter	60(9.3%)	9(8.8%)	25(5.3%)	26(36.9%)	68(8.2%)	2(1.2%)	22(2.5%)	44(85.19
		with equipment for respiratory	(2) oxygen concentrator	99(15.2%)	9(8.5%)	54(11.4%)	36(50.7%)	61(7.5%)	1(0.6%)	23(2.9%)	37(73.49
		care, including safe oxygen use	(3) filled oxygen cylinder	47(7.3%)	7(6.8%)	16(3.4%)	24(34%)	99(12.4%)	5(10.9%)	44(6%)	50(85.79
		usc	(4) oxygen distribution system	27(4.2%)	2(1.9%)	15(3.2%)	10(14.2%)	60(8.5%)	1(9.1%)	316(60.7%) 4 317(58.1%) 4 402(74.5%) 4 0(0%) 5  269(47.5%) 3 434(76.9%) 4 314(56.7%) 5 419(77.1%) 5 18(3%) 2 350(65.9%) 5 22(2.5%) 4 23(2.9%) 3 44(6%) 5 16(2.1%) 4 446(81.1%) 3 446(84%) 4 263(50.1%) 3	43(78.49
	Medicines and	The proportion of facilities with commodities for	(1) glucometer	151(23.4%)	32(31.2%)	58(12.3%)	61(85.8%)	532(79.7%)	48(72.9%)	446(81.1%)	38(77.79
	commodities	monitoring blood glucose	(2) glucometer strips	129(20%)	24(23.4%)	48(10.1%)	57(80.2%)	537(82%)	46(71%)	446(84%)	45(82.5
		The proportion of facilities with medicines and	(1) hand-washing soap	313(48.7%)	57(55.4%)	211(44.9%)	45(63.5%)	334(48.2%)	36(44.9%)	263(50.1%)	35(34.69
		commodities for infection management	(2) disposable latex gloves	622(96.4%)	96(93%)	458(97.2%)	68(95.8%)	584(86.7%)	55(81.7%)	480(91.5%)	49(44.49
	Staff and guidelines	The proportion of facilities with at least one health worker	(1) Integrated Management of Pregnancy and Childbirth (IMPAC)	137(21.2%)	3(2.9%)	103(21.9%)	31(44.2%)	223(37.8%)	10(19%)	190(41.8%)	23(21.39
		who has received training about the following in the past	(2) Comprehensive Emergency Obstetric and Newborn Care (CEmONC)	133(20.6%)	5(4.8%)	97(20.6%)	31(44.3%)	170(27.5%)	9(17.5%)	141(29.6%)	20(18.69
		24 months	(3) Routine care for labor and normal vaginal delivery	214(33.2%)	3(2.9%)	166(35.3%)	45(64.1%)	236(43.5%)	10(46.1%)	205(45.4%)	21(18.8
		The proportion of facilities with the following guidelines	guidelines on management of preterm labor	226(34.7%)	0(0%)	190(40.2%)	36(50.6%)	130(18%)	0(0%)	107(17.7%)	23(57.69

<sup>\* :</sup> data unavailable

Four readiness categories based on five WHO criteria		The proportion of facilities w	ith the indicators available	Sub-Saharan Africa Tanzania 2014-2015			
on live wife criteria				Overall	Level 1	Level 2	Level 3
1. Assess GA accurately and identify imminent preterm labor	Equipment	The proportion of facilities with a functional ultrasound mac	hine in use	223(4.6%)	6(2.9%)	23(1%)	194(65.1%)
2. Identify maternal infections	Equipment	The proportion of facilities with this equipment	thermometer	654(56.6%)	0(0%)	417(62.7%)	237(84.6%)
	Diagnostics	The proportion of facilities with the following diagnostics	(1) hematology analyzer	233(6.7%)	12(10.1%)	52(3%)	169(58.2%)
			(2) HIV rapid diagnostic test	879(82.1%)	76(77.4%)	573(82.6%)	230(83%)
			(3) syphilis rapid diagnostic test	455(40%)	50(41.1%)	275(39.5%)	130(45.4%)
3. Provide adequate childbirth	Equipment	ment The proportion of facilities with the following equipment	(1) delivery pack	838(74.4%)	0(0%)	575(83.2%)	263(97.1%)
care		to perform CEmONC (obstetric related)	(2) cord clamp	711(64.7%)	0(0%)	487(72.4%)	224(83.3%)
			(3) manual vacuum extractor	176(4.7%)	0(0%)	26(2.2%)	150(54.5%)
			(4) vacuum aspiration kit or D&C kit	197(6.6%)	0(0%)	77(5.1%)	120(45.7%)
			(5) forceps (large)	821(72.1%) 0(0%)	0(0%)	568(80.7%)	253(93.3%)
			(6) forceps (medium)	896(82.2%)	0(0%)	634(92.5%)	262(96.9%)
	Medicines	The proportion of facilities with the following medicines	(1) parenteral antibiotics	363(28.4%)	0(0%)	211(30.7%)	152(54.4%)
	and		(2) parenteral anticonvulsants (diazepam)	580(48.9%)	0(0%)	369(53.9%)	211(76.7%)
	commodities		(3) parenteral oxytocin	818(69.8%)	0(0%)	562(77.9%)	256(93.2%)
	Staff and	The proportion of facilities that has the following staff	(1) a health worker who can perform C/S	238(4.4%)	0(0%)	0(0%)	238(83.6%)
	guidelines		(2) an anesthetist	215(3.9%)	0(0%)		215(74.3%)
		The proportion of facilities with the following guidelines	(1) national guidelines for BEmONC	368(25%)	0(0%)	249(27.3%)	119(43.2%)
			(2) national guidelines for CEmONC	134(7.9%)	0(0%)	79(8.1%)	55(20.7%)
4. Provide adequate preterm	Equipment	Equipment The proportion of facilities with the following equipment for neonatal resuscitation	(1) suction bulb or penguin sucker	652(57.4%)	0(0%)	427(63.9%)	225(80.7%)
newborn care			(2) stethoscope (in general)	732(64%)	0(0%)	490(71.4%)	242(86.4%)
			(3) newborn masks, neonatal size self-inflating bag	772(67.4%) 0(0%)	512(75%)	260(94.8%)	
		The proportion of facilities with equipment for thermal	(1) incubator	97(2.4%)	0(0%)	17(1.1%)	80(28%)
		care	(2) other external heat source	188(5.6%)	0(0%)	41(3.4%)	147(52.5%)
		The proportion of facilities with equipment for respiratory	(1) pulse oximeter	84(2.8%)	8(10.1%)	9(0.4%)	67(25.3%)
		care, including safe oxygen use	(2) oxygen concentrator	159(5.2%)	11(12.2%)	45(2.1%)	103(38.7%)
			(3) filled oxygen cylinder	105(3.7%)	8(11.1%)	20(1%)	77(29.7%)
			(4) oxygen distribution system	51(2.1%)	5(5.5%)	12(0.9%)	34(12.9%)
	Medicines	The proportion of facilities with commodities for	(1) glucometer	453(19.3%)	40(42.2%)	181(12%)	232(86%)
	and	monitoring blood glucose	(2) glucometer strips	395(17.8%)	35(39.3%)	147(11%)	213(78.4%)
	commodities	The proportion of facilities with medicines and	(1) hand-washing soap	697(63.5%)	67(64.1%)	434(63.1%)	196(70%)
		commodities for infection management	(2) disposable latex gloves	996(94%)	98(94.1%)	640(94%)	258(94.9%)
	Staff and	The proportion of facilities with at least one health worker	(1) Integrated Management of Pregnancy and Childbirth (IMPAC)	228(16%)	3(5.1%)	138(16.6%)	87(31.5%)
	guidelines	who has received training about the following in the past	(2) Comprehensive Emergency Obstetric and Newborn Care (CEmONC)	252(14.7%)	2(5%)	146(14.6%)	104(36.8%)
		24 months	(3) Routine care for labor and normal vaginal delivery	308(20.1%)	6(9.2%)	185(20.2%)	117(42.6%)
		The proportion of facilities with the following guidelines	guidelines on management of preterm labor	153(10.2%)	0(0%)	83(10.7%)	70(24.9%)


<sup>\* :</sup> data unavailable

## Supplemental Figure 1. Heatmap of facility readiness for all facilities by country

#### Readiness of all facilities functional ultrasound 3.6% 12.3% 10.8% 10.7% 4.5% 10% 0.2% 4.6% 58.6% 20.7% 33.4% 21% 56.6% 16.1% hematology analyzer 2.7% 8.6% 30.5% 5.4% 5.7% 8.8% 6.7% HIV RDT 25.8% 44.2% 29.1% 21.2% syphilis RDT 21.9% 3% 12.8% 20.9% 11.8% 11.1% 14.8% 68.8% 40% delivery pack 19% 50.6% 30.5% 22.5% 46.8% cord clamp 15.8% 33.8% 23.4% 69.1% 4.8% 12.1% 7.2% 33.9% 11% 4.7% manual vacuum extractor 5.5% 16.5% D and C kit 60.5% 5.8% 10.9% 10.8% 38.4% 10% 20.1% 49.4% 6.6% 5.9% large forceps 19.7% 40.6% 5.4% 23.9% 46.1% 5.2% medium forceps 19.4% 5.3% 23.4% parenteral antibiotics 42% 4.6% 34.4% 19.3% 36.4% 16.4% 48.1% 51.3% 28.4% parenteral anticonvulsants 45.1% 4.7% 14.7% 12.1% 55.4% 10.4% 51.6% 48.9% parenteral oxytocin 7.5% 50.5% 27.7% 22.8% CS health worker 32.5% 2.5% 3.5% 5.8% 20.5% 2.2% 8.7% 3.5% 4.4% readiness level 26.6% 1.9% 3.2% 4.6% 12.3% 2.2% 7.2% 3.6% 3.9% 0-20% BEMONC national guidelines 5.1% 2.8% 11.5% 40.9% 25% 21-40% 41-60% CEMONC national guidelines 5.1% 2.2% 13.4% 24.7% 4.3% 22.8% 41.9% 7.9% 61-80% 57.4% suction bulb 15.8% 22.3% 35% 21.3% 81-100% stethoscope 23.2% 38.1% 23.1% 51.1% 64% NA newborn masks and self inflating bag 13.1% 47.7% 26.9% 22.3% 21.6% 55.4% 2.2% 4.5% 3% 5.7% 6.6% incubator 6.4% 4.5% 2.4% other external heat source 4.2% 33.6% 17.2% 18.2% 9.4% 12% 58.4% 5.6% pulse oximeter 53.7% 3% 42% 16.7% 2.8% 26.8% 9.3% 8.2% 2.8% oxygen concentrator 48.2% 3.2% 11.7% 2.4% 11.2% 15.2% 7.5% 10.8% 5.2% filled oxygen cylinder 6.6% 22.5% 16.1% 1.8% 13% 7.3% 12,4% 3.7% oxygen distribution system 13.3% 1.6% 3.2% 4.8% 4.2% 8.5% 2.1% 21.1% 34% alucometer 37% 19.4% 49.8% 21% 23.4% 19.3% 17.4% 29.6% 19 3% 20% glucometer strips 34% 21.3% 45.6% 17.8% 48.2% hand washing soap 52.9% 48.4% 45.3% 48.7% disposable latex gloves training about IMPAC 12.9% 15% 4.5% 27.8% 34.5% 2.4% 21.2% 37.8% 16% training about CEmONC 4.2% 10.6% 4.4% 23.5% 29.6% 2% 20.6% 27.5% 14.7% training about normal vaginal delivery 13.5% 18.2% 11.1% 27.9% 33.6% 2.8% 33.2% 43.5% 20.1% preterm labor management guidelines 5.1% 3.2% 6.4% 11.4% 7.2% 34.7% 18% 10.2% AFG18 BD17 NP21 HT17 DRC17 ET21 SN1819 T714 country and survey year

AFG18. Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haitl 2017; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 20121-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015; RDT: rapid diagnostic test; BEmONC: Basic Emergency Obstetrics and Newborn Care; CEmONC: Comprehensive Emergency Obstetrics and Newborn Care; IMPAC: Integrated Management of Pregnancy and Childbirth; NA: not applicable

#### **Supplemental Figure 2.** Heatmap of facility readiness for level 1 facilities by country



AFG18: Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 20121-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015; RDT: rapid diagnostic test; BEmONC: Basic Emergency Obstetrics and Newborn Care; CEmONC: Comprehensive Emergency Obstetrics and Newborn Care; IMPAC: Integrated Management of Pregnancy and Childbirth; NA: not applicable

## Supplemental Figure 3. Heatmap of facility readiness for level 2 facilities by country

preterm labor management guidelines

0%

AFG18

13.6%

BD17

NP21

#### Readiness of level 2 facilities functional ultrasound 1.7% 10.3% 5.5% 1.2% 6.1% 1.5% 0.2% thermometer hematology analyzer 1.7% 5.4% 34.5% 2% 12.4% 1.3% 10.5% 3% HIV RDT 7.2% 26.6% 39.3% syphilis RDT 7.2% 2.7% 16.2% 23.5% 9.9% 29.1% 11.4% 39.5% delivery pack 28.6% cord clamp 37.3% manual vacuum extractor 17.4% 14.7% 17.6% 7.8% 5.1% 34.8% 7.6% 2.2% D and C kit 37% 14.5% 14.5% 21.6% 26.4% 38.2% 20.4% 55.7% 5.1% large forceps 6.7% 5.4% medium forceps 7.9% 4.6% parenteral antibiotics 50% 7.6% 64% 42.8% 34.3% 64.6% 51.9% 60.7% 30.7% 50% 22.4% 52.7% 39.3% 58.1% 53.9% parenteral anticonvulsants 8.6% 28.3% parenteral oxytocin 32.2% 21.6% CS health worker 0% 0% 0% 0% 0% 0% 0% 0% 0% anesthetist 0% 0% 0% 0% 0% 0% 0% 0% 0% BEmONC national guidelines 0% 10.9% 45% 48.9% 27.3% indicator CEMONC national guidelines 8.7% 34.5% 15.5% 47.5% 0% 23.2% 24.8% 8.1% suction bulb 40.4% 58.7% stethoscope 37% 48% 47.8% newborn masks and self inflating bag 21% 11.1% 2.7% 4.7% 9.5% 0.6% 14.4% 1.7% 3% 1.1% incubator other external heat source 16.7% 10.7% 35.3% 32.7% 12 4% 6.5% 3.4% pulse oximeter 50.4% 0.4% 5.3% 2.5% 0.4% 21% 0% 14.7% 15.7% 0.5% 6.8% oxygen concentrator 5.8% 11.4% 2.9% 2.1% filled oxygen cylinder 13.2% 30.3% 21.7% 0.3% 7.9% 3.4% 6% 1% oxygen distribution system 5.6% 2% 0.6% 4.4% 2.6% 3.2% 2.1% 0.9% 55.5% 10.6% 24.9% 18.2% 12.3% 12% glucometer strips 55.5% 9.9% 21.9% 57.2% 15.6% 10.1% 11% 45.6% 44.9% 50.1% hand washing soap 22.7% 52.1% 51.8% disposable latex gloves 50.5% training about IMPAC 0% 11.7% 7.7% 42.8% 33.8% 6.6% 21.9% 41.8% 16.6% training about CEmONC 0% 6.1% 6.8% 35.7% 28.6% 5.6% 20.6% 29.6% 14.6% training about normal vaginal delivery 0% 14.8% 20.4% 43.6% 33.5% 6.5% 35.3% 45.4% 20.2%

AFG18: Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 20121-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015; RDT: rapid diagnostic test; BEmONC: Basic Emergency Obstetrics and Newborn Care; IMPAC: Integrated Management of Pregnancy and Childbirth; NA: not applicable

8.8%

DRC17

country and survey year

27.1%

ET21

40.2%

MW13

17.7%

SN1819

10.7%

TZ14

15.6%

HT17

readiness level

0-20%

21-40%


41-60%

61-80%

81-100%

NA


#### Supplemental Figure 4. Heatmap of facility readiness for level 3 facilities by country



AFG18. Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 20121-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015; BC17: Tanzania 2014-2015; CEmONC: Comprehensive Emergency Obstetrics and Newborn Care; IMPAC: Integrated Management of Pregnancy and Childbirth; NA: not applicable

### Supplemental Figure 5. ACS utilization and corticosteroid availability by facility level


Corticosteroids availability and ACS utilization by country and facility level



AFG18. Afghanistan 2018-2019, BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017-2018; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 2021-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015

### Supplemental Figure 6. Differences in overall readiness indexes by antenatal corticosteroids utilization for all facilities


#### Overall readiness index for all facilities by ACS utilization (%)



AFG18 Afghanistan 2018-2019 BD17 Bandladesh 2017-2018 NP21 Nepal 2021 HT17 Hatti 2017-2018 DRC17 the Demographic Republic of Congo 2017-2018 FT21 Ethicoia 2021-2022 MW13 Malawi 2013-2014 SN1819 Senegal 2018 and 2019 T214 Tanzania 2014-20

## Supplemental Figure 7. Differences in overall readiness indexes by antenatal corticosteroids utilization for level 2 facilities


#### Overall readiness index for level 2 facilities by ACS utilization



AFG18: Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017-2018; DRC17: the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 2021-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015

## Supplemental Figure 8. Differences in overall readiness indexes by antenatal corticosteroids utilization for level 3 facilities

#### Overall readiness index for level 3 facilities by ACS utilization



AFG18: Afchanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017-2018; DRC17; the Demographic Republic of Congo 2017-2018; ET21: Ethiopia 2021-2022; MW13: Malawi 2013-2014; SN1819; Senegal 2018 and 2019; T214: Tanzania 2014-2015